Barrow Hanley Mewhinney & Strauss LLC lessened its stake in Medtronic PLC (NYSE:MDT – Free Report) by 1.7% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 3,687,628 shares of the medical technology company’s stock after selling 62,891 shares during the period. Barrow Hanley Mewhinney & Strauss LLC’s holdings in Medtronic were worth $318,205,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently made changes to their positions in the company. Activest Wealth Management grew its stake in Medtronic by 470.9% during the 3rd quarter. Activest Wealth Management now owns 314 shares of the medical technology company’s stock worth $27,000 after buying an additional 259 shares during the last quarter. Team Financial Group LLC purchased a new stake in Medtronic in the third quarter valued at approximately $31,000. Avion Wealth lifted its stake in Medtronic by 97.8% in the third quarter. Avion Wealth now owns 362 shares of the medical technology company’s stock valued at $31,000 after buying an additional 179 shares during the last quarter. IAG Wealth Partners LLC acquired a new stake in shares of Medtronic in the second quarter valued at approximately $30,000. Finally, Pin Oak Investment Advisors Inc. acquired a new stake in shares of Medtronic in the second quarter valued at approximately $32,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.
Medtronic Stock Performance
NYSE:MDT opened at $99.88 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The firm has a market cap of $127.75 billion, a price-to-earnings ratio of 17.99, a price-to-earnings-growth ratio of 2.41 and a beta of 0.56. The firm’s fifty day moving average price is $94.62 and its 200 day moving average price is $88.45. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33.
Medtronic (NYSE:MDT – Get Free Report) last released its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.06. The company had revenue of $9.76 billion for the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The firm’s quarterly revenue was up 13.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.98 EPS for the current year.
Insider Activity at Medtronic
In other Medtronic news, CEO Geoffrey Martha sold 50,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the sale, the chief executive officer owned 277,866 shares of the company’s stock, valued at approximately $26,397,270. This trade represents a 15.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Marinaro sold 10,420 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the sale, the executive vice president owned 105,916 shares in the company, valued at $10,167,936. The trade was a 8.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 61,903 shares of company stock worth $5,889,203 over the last three months. 0.27% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on MDT. Weiss Ratings raised shares of Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, October 19th. UBS Group reiterated a “cautious” rating on shares of Medtronic in a research report on Wednesday, October 14th. Stifel Nicolaus increased their price target on shares of Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a research note on Wednesday, September 2nd. Mizuho set a $115.00 price objective on shares of Medtronic in a research report on Wednesday, September 2nd. Finally, Piper Sandler upgraded shares of Medtronic from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $85.00 to $120.00 in a research note on Tuesday. Eighteen research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $104.17.
Check Out Our Latest Research Report on Medtronic
About Medtronic
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
Recommended Stories
- Five stocks we like better than Medtronic
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
